The Impact of Using a Non-motorised Physical Assistance Device on the Prevention of Musculoskeletal Disorders Amongst Care-givers (TM2S)
This experimental study uses a Single-Case Experimental Design (SCED) with multiple baselines across participants to evaluate the impact of a non motorized assistive device (DAP) on muscle effort in care givers during their professional activities. Each participant completes a 12-day protocol consisting of three phases (A1 - B - A2), with the initial baseline (A1, no device) randomized between 2 and 6 days, followed by a 6-day intervention phase (B, wearing the non-motorized DAP), and a final withdrawal phase (A2, no device) adjusted to complete the 12-day period. Muscle effort is continuously quantified as a percentage of maximum voluntary contraction using mechanomyographic sensors (MOTEN Technologies) placed on the lumbar and biceps muscles, as well as the quadriceps at the Fondation Saint-Hélier site.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Bastien Fraudet
- Phone Number: +33299295043
- Email: bastien.fraudet@fondationsainthelier.com
Study Locations
-
-
-
Landivisiau, France
- Fondation Ildys - EHPAD Saint Vincent
-
Contact:
- Manon Le Goff
- Phone Number: +33298028308
- Email: manon.legoff@ildys.org
-
Principal Investigator:
- Sylvia Courtes
-
Ploemeur, France, 56270
- Centre Mutualiste de Rééducation et de Réadaptation Fonctionnelles (CMRRF) de Kerpape
-
Contact:
- Marie Caroline Fortuné
- Phone Number: +33297826023
- Email: marie-caroline.fortune@vyv3.fr
-
Principal Investigator:
- Cécile Diot
-
Rennes, France
- Fondation Saint Helier
-
Contact:
- Estelle Cézé
- Phone Number: +33299295043
- Email: estelle.ceze@fondationsainthelier.com
-
Principal Investigator:
- Estelle Cézé
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged 18 years and older.
- Height between 160 cm and 200 cm.
- Professional care-giver working in SMR (Medical and Rehabilitation Care) or medico-social departments of partner healthcare facilities.
- Willing to wear the non-motorized DAP under the conditions defined by the protocol.
- Affiliated with or beneficiary of a national social security scheme.
- Having provided free and informed written consent.
Exclusion Criteria:
- Self-reported back, leg, or knee pathology that raises doubts regarding the safe use of the non-motorized DAP without prior medical clearance.
- Pregnant, parturient, or breastfeeding women.
- Persons deprived of liberty by a judicial or administrative decision (including legal guardianship, trusteeship, or court protection).
- Persons receiving psychiatric care or admitted to a healthcare or social establishment for reasons other than research.
- Persons in emergency situations unable to express prior informed consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Non-motorized DAP Intervention
Single group following a 12-day A1-B-A2 SCED protocol. Participants undergo a randomized baseline of 2-6 days without the device (A1), a 6-day intervention phase wearing the non-motorized DAP during work activities (B), and an adjusted withdrawal phase without the device (A2). |
Participants wear a non-motorized device for posture assistance (DAP) during their regular professional activities as nurse's aides for 6 consecutive days (Phase B of the 12-day A1-B-A2 SCED protocol). Muscle effort is continuously monitored using mechanomyographic sensors (MOTEN Technologies).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Maximum Voluntary Contraction (% MVC) of target muscle groups
Time Frame: Daily during work hours over the 12-day study protocol
|
Muscle effort is continuously quantified via mechanomyography (MMG) using MOTEN Technologies sensors. The primary outcome is the muscle effort level expressed as a percentage of the individual's maximum voluntary contraction (% MVC) for each monitored muscle group (lumbar and biceps muscles across all sites; quadriceps muscles at the Fondation Saint-Hélier site). Measures are compared across the baseline (A1), intervention (B), and withdrawal (A2) phases. |
Daily during work hours over the 12-day study protocol
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in postural strain measured by mechanomyography (MMG)
Time Frame: Daily during work hours over the 12-day study protocol
|
Postural strain during daily professional activities is evaluated using mechanomyographic (MMG) sensors (MOTEN Technologies) placed on target muscle groups. Measures are compared across the baseline (A1), intervention (B), and withdrawal (A2) phases. |
Daily during work hours over the 12-day study protocol
|
|
Change in perceived effort score using a Numerical Rating Scale (NRS)
Time Frame: Twice daily (after each half-day work shift) over the 12-day study protocol
|
Perceived exertion during work tasks is assessed using a 0 to 10 Numerical Rating Scale (NRS/EVN), where 0 represents very low effort and 10 represents very high effort. |
Twice daily (after each half-day work shift) over the 12-day study protocol
|
|
Change in perceived fatigue score using a Numerical Rating Scale (NRS)
Time Frame: Twice daily (before and after each full work day) over the 12-day study protocol
|
Subjective physical fatigue is assessed using a 0 to 10 Numerical Rating Scale (NRS/EVN), where 0 represents very low fatigue and 10 represents very high fatigue. |
Twice daily (before and after each full work day) over the 12-day study protocol
|
|
User satisfaction score with the non-motorized DAP (ESAT questionnaire)
Time Frame: At the end of Phase B (Day 6 of wearing the device)
|
User satisfaction with the assistive device will be assessed using the 8-item Device subscale of the Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST 2.0 / ESAT). Items are rated on a 5-point Likert scale from 1 to 5, yielding a total sum score ranging from 8 to 40, where higher scores indicate greater satisfaction |
At the end of Phase B (Day 6 of wearing the device)
|
|
Acceptability score based on the UTAUT model
Time Frame: Baseline (prior to Phase A1/B) and Post-Intervention (At the end of day 6 of phase B)
|
Technology acceptance will be assessed across the constructs of the Unified Theory of Acceptance and Use of Technology (UTAUT) questionnaire. Each item is rated on a 7-point Likert scale from 1 (strongly disagree) to 7 (strongly agree). Each item also belongs one of several subscales. Mean scores are calculated separately for each subscale, ranging from 1 to 7, where higher scores indicate greater technology acceptance. |
Baseline (prior to Phase A1/B) and Post-Intervention (At the end of day 6 of phase B)
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2026-A01360-51
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.